Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10245330512331389755 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adenoid basal cell carcinoma: An underrecognized cervical malignancy.
Gynecol Oncol Rep
February 2025
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New Hyde Park, NY 11040, United States.
Introduction: Adenoid basal cell carcinoma is a rare cervical malignancy which is indolent in nature but resembles more commonly occurring aggressive malignancies.
Cases: Here we describe three cases of cervical adenoid basal cell carcinoma. All patients had a history of cervical dysplasia with high-risk HPV.
Conquering Overtreatment of DCIS: Lessons from PRECISION.
Cancer Discov
January 2025
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
As we cannot reliably distinguish indolent, low-risk ductal carcinoma in situ (DCIS) from potentially progressive, high-risk DCIS, all women with DCIS diagnosis undergo intensive treatment without any benefit. The PREvent ductal Carcinoma In Situ Invasive Overtreatment Now team was established to unravel DCIS biology and develop new multidisciplinary approaches for accurate risk stratification to tackle the global problem of DCIS overdiagnosis and overtreatment. See related article by Bressan et al.
View Article and Find Full Text PDFUnusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy.
Leuk Lymphoma
January 2025
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- FT596 is a novel cancer therapy using iPSC-derived CAR NK cells targeting CD19, designed to assess its safe dosage and effectiveness alone and with rituximab in patients with B-cell lymphoma.
- This phase 1 trial involved patients with relapsed or refractory B-cell lymphoma, administering FT596 after chemotherapy, with separate regimens for those receiving rituximab and those who did not.
- The study measured potential side effects while determining the optimal dose of FT596 and allowed modifications to the treatment based on patient tolerance and response.
Automatic Characterization of Prostate Suspect Lesions on T2-Weighted Image Acquisitions Using Texture Features and Machine-Learning Methods: A Pilot Study.
Diagnostics (Basel)
January 2025
Department of Medical Imaging, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
: Prostate cancer (PCa) is the most frequent neoplasia in the male population. According to the International Society of Urological Pathology (ISUP), PCa can be divided into two major groups, based on their prognosis and treatment options. Multiparametric magnetic resonance imaging (mpMRI) holds a central role in PCa assessment; however, it does not have a one-to-one correspondence with the histopathological grading of tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!